Drug Profile
ASP 3291
Alternative Names: ASP3291Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Developer Telsar Pharma
- Class Anti-inflammatories; Cyclic peptides
- Mechanism of Action Melanocortin type 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ulcerative colitis
Most Recent Events
- 01 Apr 2014 Telsar Pharma completes a phase II trial in Ulcerative colitis in USA, Canada, Israel and Serbia (NCT01612039)
- 17 Jan 2014 Telsar Pharma completes enrolment in its phase II trial for Ulcerative colitis in USA (NCT01612039)
- 01 Jul 2012 Phase-II clinical trials in Ulcerative colitis in Canada, Israel and Serbia (PO)